Coagulation and sepsis: A winding road ahead

Critical Care Medicine

Volumn 40, Issue 9, 2012, Pages 2733-2734

  Levi, Marcel ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

coagulation; disseminated intravascular coagulation; inflammation; sepsis

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTITHROMBIN; FIBRIN; RECOMBINANT THROMBOMODULIN;

AUTOPSY; BLEEDING; BLOOD CLOTTING; DISEASE ASSOCIATION; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; EDITORIAL; HEMOSTASIS; HUMAN; INFLAMMATION; INNATE IMMUNITY; MORTALITY; MULTIPLE ORGAN FAILURE; PATIENT SELECTION; PRIORITY JOURNAL; SEPSIS; THROMBOSIS; TISSUE NECROSIS;

ANTICOAGULANTS; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; HUMANS; MALE; PROTEIN C; SEPSIS; SHOCK, SEPTIC;

EID: 84865511259     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31825ce4e8     Document Type: Editorial

References (12)

1. Levi M, van der Poll T: Inflammation and coagulation. Crit Care Med 2010; 38(2 Suppl):S26-S34
2. Levi M, Schultz M, van der Poll T: Disseminated intravascular coagulation in infectious disease. Semin Thromb Hemost 2010; 36:367-377
3. Anas AA, Wiersinga WJ, de Vos AF, et al: Recent insights into the pathogenesis of bacterial sepsis. Neth J Med 2010; 68:147-152
4. Fourrier F, Chopin C, Goudemand J, et al: Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992; 101:816-823
5. Dhainaut JF, Yan SB, Joyce DE, et al: Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost 2004; 2:1924-1933
6. Bakhtiari K, Meijers JC, de Jonge E, et al: Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation. Crit Care Med 2004; 32: 2416-2421
7. Levi M, Lowenberg E, Meijers JC: Recombinant anticoagulant factors for adjunctive treatment of sepsis. Semin Thromb Hemost 2010; 36:550-557
8. Fourrier F: Severe sepsis, coagulation, and fibrinolysis: Dead end or one way? Crit Care Med 2012; 40:2704-2708
9. Kienast J, Juers M, Wiedermann CJ, et al.; KyberSept investigators: Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 2006; 4:90-97
10. Levy MM, Dellinger RP, Townsend SR, et al: The Surviving Sepsis Campaign: Results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med 2010; 36: 222-231
11. Casserly B, Gerlach H, Phillips GS, et al: Evaluating the use of recombinant human activated protein C in adult severe sepsis: Results of the Surviving Sepsis Campaign*. Crit Care Med 2012; 40:1417-1426
12. Tromp M, Tjan DH, van Zanten AR, et al: The effects of implementation of the Surviving Sepsis Campaign in the Netherlands. Neth J Med 2011; 69:292-298